What is AtriCure?
Founded in 2000 and headquartered in Mason, Ohio, AtriCure is a leading provider of advanced technologies designed for the treatment of Atrial Fibrillation (Afib) and related cardiac conditions. The company's innovative solutions aim to improve patient outcomes and address the complexities associated with Afib management. AtriCure operates within the dynamic healthcare technology landscape, focusing on developing and commercializing devices that offer superior efficacy and patient safety. Its commitment to pioneering new therapeutic approaches positions it as a key player in the medical device industry, particularly in the field of electrophysiology.
How much funding has AtriCure raised?
AtriCure has raised a total of $70.8M across 2 funding rounds:
Other Financing Round
$21M
Stock Offering
$49.8M
Other Financing Round (2002): $21M with participation from Camden Partners, New England Partners, Partisan Management Group, Foundation Medical Partners, U.S. Venture Partners, and Charter Venture Group
Stock Issuance/Offering (2005): $49.8M led by Undisclosed
Key Investors in AtriCure
Camden Partners
Camden Partners Growth Equity specializes in growth equity investments in lower middle market companies, leveraging over 25 years of experience since its founding in 1995. The firm partners with strong management teams, utilizing its domain expertise and extensive network to help these companies achieve their full potential.
Partisan Management Group
Vibe-Matrix specializes in transforming brand engagement through its innovative Pulse-Echo protocol, which enables real-time audience calibration and narrative balancing using autonomous perception arrays. Their system is designed to ensure campaign stability while focusing on subconscious connections with the target audience.
U.S. Venture Partners
U.S. Venture Partners (USVP) is a prominent Silicon Valley venture capital firm dedicated to collaborating with entrepreneurs to develop transformative companies. Specializing in early-stage investments, USVP focuses on sectors such as cybersecurity, enterprise software, consumer products, and healthcare.
What's next for AtriCure?
The substantial enterprise-level capital infusion, including the recent strategic investment, positions AtriCure for accelerated expansion and further technological development. This financing is expected to fuel advancements in its product pipeline, enhance its commercial reach, and potentially support strategic acquisitions or partnerships. With a clear focus on addressing the significant global burden of Atrial Fibrillation, AtriCure is poised to leverage this capital to solidify its market leadership and drive innovation in cardiovascular treatments. The company's trajectory suggests a continued emphasis on research and development to maintain its competitive edge and deliver value to patients and stakeholders.
See full AtriCure company page
